ALEXANDRIA, Va., June 25 -- United States Patent no. 12,338,269, issued on June 24, was assigned to Medicenna Therapeutics Inc. (Toronto).
"IL-2 superagonists in combination with anti-PD-1 antibodies" was invented by Fahar Merchant (Vancouver, Canada) and Shafique Fidai (Vancouver, Canada).
According to the abstract* released by the U.S. Patent & Trademark Office: "Human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2RBeta receptor as compared to wild-type IL-2 for use in combination therapies with anti-PD-1 antibodies for the treatment of cancer. Also provided are pharmaceutical compositions that include such anti-PD-1 antibodies and ...